Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.
Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.
复制标题
DOI：
10.1007/s42399-020-00610-8
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Hassan A
中科院分区：
文献类型：
--
作者：
Ahmed MH;Hassan A
世界卫生组织（世卫组织）于二零二零年三月中旬宣布COVID-19（新型冠状病毒）为全球大流行病，此前该疾病在几个月内蔓延至150多个国家和地区，导致数万例病例。迄今为止，还没有有效的药物治疗方法。除此之外，新型疫苗尚未获得批准，因为确定其疗效需要时间。本研究旨在总结关于糖皮质激素（如地塞米松）治疗COVID-19的证据。于2020年9月7日对Google Scholar数据库、MEDLINE和PubMed进行了电子检索。对世界卫生组织的COVID-19研究文章数据库进行了进一步检索。讨论了最近的研究结果，这些研究证明了皮质类固醇对COVID-19和其他冠状病毒相关肺炎的体外和体内活性。低剂量皮质类固醇（地塞米松）可以降低严重COVID-19疾病患者的死亡率;然而，它们对轻度疾病患者的死亡率没有影响。此外，不提倡自由使用皮质类固醇，因为高剂量的药物可能弊大于利。
The World Health Organization (WHO) declared COVID-19 (novel coronavirus) as a global pandemic in the middle of March 2020, after the disease spread to more than 150 countries and territories leading to tens of thousands of cases within a couple of months. To date, there are no effective pharmaceutical treatments available. As well as that, the novel vaccines have not yet been approved as establishing their efficacy will take time. This study aims to summarize the evidence regarding corticosteroids such as dexamethasone for the treatment of COVID-19. Electronic searches were conducted on 7 September 2020 on Google Scholar database, MEDLINE and PubMed. A further search was conducted on the World Health Organization’s COVID-19 research article database. The findings of recent investigations that proved, both, the in vitro and in vivo activity of corticosteroids against COVID-19 and other coronavirus-related pneumonia were discussed. Low doses of corticosteroids (dexamethasone) could reduce the mortality in patients with severe COVID-19 disease; however, they had no effect on the mortality rate of those patients with a mild form of the condition. Moreover, the liberal use of corticosteroids was not advocated for, as high doses of the drug can cause more harm than good.